Local ocular safety of the subconjunctival injection of cetuximab in rabbits

[1]  M. V. Cicinelli,et al.  Clinical Management of Ocular Surface Squamous Neoplasia: A Review of the Current Evidence , 2018, Ophthalmology and Therapy.

[2]  C. S. Moon,et al.  Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications. , 2014, Ophthalmology.

[3]  D. Wakefield,et al.  Matrix metalloproteinases and their inhibitors in squamous cell carcinoma of the conjunctiva. , 2013, The ocular surface.

[4]  A. Mitra,et al.  Ocular drug delivery systems: An overview. , 2013, World journal of pharmacology.

[5]  U. Keklikçi,et al.  The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.

[6]  E. Midena,et al.  Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study , 2010 .

[7]  A. Zaki,et al.  Management of Intraepithelial and Invasive Neoplasia of the Cornea and Conjunctiva: A Long-Term Follow Up , 2009, Cornea.

[8]  R. Mehra,et al.  The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. , 2008, Clinical advances in hematology & oncology : H&O.

[9]  B. Melichar,et al.  Eye complications of cetuximab therapy. , 2007, European journal of cancer care.

[10]  A. Schueler,et al.  Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Ramanathan,et al.  Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer. , 2006, Clinical colorectal cancer.

[12]  K. Colby,et al.  Topical Medical Therapies for Ocular Surface Tumors , 2006, Seminars in ophthalmology.

[13]  F. Lee,et al.  Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft , 2005, Cancer Chemotherapy and Pharmacology.

[14]  P. Jeffrey,et al.  Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.

[15]  J. Pe’er.  Ocular surface squamous neoplasia. , 2005, Ophthalmology clinics of North America.

[16]  B. Burtness,et al.  Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. , 2005, Drugs of today.

[17]  C. Shields,et al.  Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors. , 2004, Ophthalmology.

[18]  G. Snibson,et al.  Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia. , 1997, Ophthalmology.

[19]  J. Frucht-Pery,et al.  Mitomycin C therapy for corneal intraepithelial neoplasia. , 1994, American journal of ophthalmology.

[20]  M. Soytürk,et al.  Long-term results of cryotherapy on malignant epithelial tumors of the conjunctiva. , 1989, American journal of ophthalmology.

[21]  C. Shields,et al.  Tumors of the conjunctiva and cornea. , 2004, Survey of ophthalmology.

[22]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[23]  C. Karp,et al.  Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. , 2001, Ophthalmology.